Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorMassachusetts General Hospital
About this trial
The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.
Eligibility criteria
Qualifiers
Age ≥ 18 years old at time of signing informed consent
Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment
Able to provide informed consent
Disqualifiers
Current pregnancy (positive urine hCG) or plans to become pregnant in the next 6 months
BMI <25 kg/m2 at the time of screening
Unable to participate in a regular physical exercise program
Implanted pacemaker
Trial design
Treatments tested in this trial
- Smartwatch activity and body composition monitor
- General guidance on recommended exercise
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Samsung
Collaborator
Source ClinicalTrials.gov